BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AZD2284 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AZD2284\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06879041-11146@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20290416
DTEND;VALUE=DATE:20290417
SUMMARY:AZD2284: Phase 1 readout est. (NCT06879041)
DESCRIPTION:AZD2284\, phase 1\, Prostate Cancer.\nStudy: A Phase I Study of
  [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate
  Cancer\nEstimated primary completion: 16 April 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/azd2284#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06879041
URL:https://assetmemo.bio/drug/azd2284#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
